WGS to report earnings on February 20th after the Close.
Feb 15, 2024 20:07:02 GMT
icemandios likes this
Post by lookingforatenbagger on Feb 15, 2024 20:07:02 GMT
ir.genedx.com/news-releases/news-release-details/genedx-report-fourth-quarter-2023-financial-results-tuesday
After being hammered into the ground in the past year it is starting to look like GeneDx may survive. They released preliminary 4Q23 results on January 8th:
"Management expects GeneDx to report:
ir.genedx.com/news-releases/news-release-details/genedx-announces-preliminary-2023-financial-results
Goldman Sachs appears to think something is up. They just reported owning 1.8M shares of WGS (7% ownership) in a 13G filing. That's up from the 1.7M shares they held in 12/31/23 report. That was was up 1.4M shares they reported in their 9/30/23 report.
Morgan Stanley increased there position in WGS in their 4Q23 report from 3.5K to 784K (3% ownership)
Casdin Capital made no change to the 3.1M (12% ownership) shares they owned in 4Q23.
Maybe that's why the share price is up 3X in the last 10 weeks.
Current= $4.44
December 29, 2023 Close = $2.75
December 7th Close = $1.50
September 29, 2023 Close = $3.64
June 30, 2023 Close = $5.96
As I am sure others will be quick to point out WGS would have to be over $100/share for OPKO to be even and over $15/share just to equal the share price on 1/9/23 the day GeneDx with the stock symbol WGS was announced. We'll see next week.
After being hammered into the ground in the past year it is starting to look like GeneDx may survive. They released preliminary 4Q23 results on January 8th:
"Management expects GeneDx to report:
- revenues of at least $193 million for full year 2023
- revenues of at least $57 million in the fourth quarter, an increase of 24% year-over-year and 13% sequentially
- exome and genome test revenues of at least $38 million in the fourth quarter, an increase of 63% year-over-year and 12% sequentially
- 15,663 exome and genome test results in the fourth quarter, an increase of 99% year-over-year and 19% sequentially with exome and genome representing 27% of all tests result volume in the fourth quarter."
ir.genedx.com/news-releases/news-release-details/genedx-announces-preliminary-2023-financial-results
Goldman Sachs appears to think something is up. They just reported owning 1.8M shares of WGS (7% ownership) in a 13G filing. That's up from the 1.7M shares they held in 12/31/23 report. That was was up 1.4M shares they reported in their 9/30/23 report.
Morgan Stanley increased there position in WGS in their 4Q23 report from 3.5K to 784K (3% ownership)
Casdin Capital made no change to the 3.1M (12% ownership) shares they owned in 4Q23.
Maybe that's why the share price is up 3X in the last 10 weeks.
Current= $4.44
December 29, 2023 Close = $2.75
December 7th Close = $1.50
September 29, 2023 Close = $3.64
June 30, 2023 Close = $5.96
As I am sure others will be quick to point out WGS would have to be over $100/share for OPKO to be even and over $15/share just to equal the share price on 1/9/23 the day GeneDx with the stock symbol WGS was announced. We'll see next week.
